Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -27116.80% is 38% below its 3-year average of -19651.34%, near the low end of its 3-year range (-28454.84%–-7374.19%).
1.40% below its 12-month average of -26741.94%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2022 (2022-12-31): -25241.94%.
EBITDA MARGIN
-27116.80%
EBITDA MARGIN AVG TTM
-26741.94%
EBITDA MARGIN AVG 3Y
-19651.34%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.40%
CURRENT VS 3Y AVG
-37.99%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Candel Therapeutics, Inc.
Market Cap
$726.75M
EBITDA Margin
-27116.80%
TTM Avg
-26741.94%
3Y Avg
-19651.34%
5Y Avg
N/A
Market Cap
$723.48M
EBITDA Margin
-414.93%
TTM Avg
-258.43%
3Y Avg
-185.54%
5Y Avg
-212.52%
Market Cap
$711.21M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
Market Cap
$738.45M
EBITDA Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$709.36M
EBITDA Margin
52.93%
TTM Avg
53.31%
3Y Avg
49.89%
5Y Avg
44.80%
Market Cap
$704.20M
EBITDA Margin
-14.10%
TTM Avg
-9.55%
3Y Avg
-6.60%
5Y Avg
-0.48%
Market Cap
$763.14M
EBITDA Margin
16.77%
TTM Avg
16.87%
3Y Avg
-15.22%
5Y Avg
-3.72%
Market Cap
$765.29M
EBITDA Margin
-4915.19%
TTM Avg
-4915.19%
3Y Avg
-4915.19%
5Y Avg
-4915.19%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $726.75M | -27116.80% | -26741.94% | -19651.34% | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $723.48M | -414.93% | -258.43% | -185.54% | -212.52% |
| Apnimed, Inc. (APMD)vs › | $737.53M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $711.21M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| Design Therapeutics, Inc. (DSGN)vs › | $738.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.36M | 52.93% | 53.31% | 49.89% | 44.80% |
| Cytek Biosciences, Inc. (CTKB)vs › | $704.20M | -14.10% | -9.55% | -6.60% | -0.48% |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.14M | 16.77% | 16.87% | -15.22% | -3.72% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $765.29M | -4915.19% | -4915.19% | -4915.19% | -4915.19% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $688.30M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-27116.8%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-12-31 | -25241.94% |
| 2022-09-30 | -27987.10% |
| 2022-06-30 | -27632.26% |
| 2022-03-31 | -28454.84% |
| 2021-12-31 | -24393.55% |
| 2021-09-30 | -25832.26% |
| 2021-06-30 | -17077.42% |
| 2021-03-31 | -14938.71% |
| 2020-12-31 | -19738.71% |
| 2020-09-30 | -8722.58% |
| 2020-06-30 | -8422.58% |
| 2020-03-31 | -7374.19% |
